Results 71 to 80 of about 1,472 (172)

Immunomodulatory activity of omadacycline in vitro and in a murine model of acute lung injury

mSphere
Cystic fibrosis (CF) is characterized by chronic airway obstruction, infection, and inflammation leading to progressive loss of lung function and eventual respiratory failure.
Madeline Sanders, Paul Beringer
doaj   +1 more source

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis

Clinical Pharmacokinetics
Omadacycline offers a potential advancement in the management of infections in people with cystic fibrosis (CF) because of its spectrum of activity, intrapulmonary penetration, and oral bioavailability. A prospective single-dose, single-arm study was conducted to characterize the pharmacokinetic (PK) profile of omadacycline in people with CF ...
Madeline Sanders, Eunjin Hong, Peter S. Chung, Adupa P. Rao, Paul Beringer   +4 more
openaire   +2 more sources

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology
ObjectiveOmadacycline is a newly launched drug of tetracycline. Therefore, it is necessary to comprehensive evaluate reports on the safety of omadacycline in large, real-world populations.
Xueping Shi, Chen Wang, Xiang Liu, Li Zou, Pei Guo   +4 more
doaj   +1 more source

In vitro activity of omadacycline against bacterial isolates from bone/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015–2023)

Journal of Global Antimicrobial Resistance
Objectives: Omadacycline is an aminomethylcycline (tetracycline class) antibacterial approved by the United States Food and Drug Administration (2018) for treatment of adults with acute bacterial skin and skin structure infection (ABSSSI) and community ...
Michael D. Huband, Paul R. Rhomberg, Kelley A. Fedler, Christopher Blankers, Diane Anastasiou, Alisa W. Serio, Mariana Castanheira   +6 more
doaj   +1 more source

Efficacy of omadacycline in the treatment of Legionella pneumonia: a case report

Frontiers in Cellular and Infection Microbiology
Legionella, one of the main pathogens that causes community-acquired pneumonia, can lead to Legionella pneumonia, a condition characterized predominantly by severe pneumonia.
Yao Wang, Yao Wang, Shui-Min Yi, Shui-Min Yi, Si-Min Huang, Si-Min Huang, Wei-Xin Xu, Yi-Wen Wei, Qiang Qu, Jian Qu, Jian Qu   +10 more
doaj   +1 more source

Omadacycline treatment of severe Chlamydia psittaci pneumonia with septic shock diagnosed via metagenomic next-generation sequencing

Journal of Infection in Developing Countries
Introduction: Parrot fever, caused by Chlamydia psittaci, is a zoonotic disease typically treated with tetracyclines. Omadacycline, a novel aminomethyl tetracycline, has limited reports on its efficacy in severe Chlamydia psittaci pneumonia in the ...
Ping Xu, Zhitong Huang
doaj   +1 more source

Omadacycline successfully treated severe Legionella pneumonia after moxifloxacin treatment failure: Case series

Frontiers in Pharmacology
Legionella is a significant pathogen responsible for community-acquired pneumonia and, less commonly, for hospital-acquired pneumonia. Legionella pneumophila, the most prevalent species within the Legionella genus, accounts for 80%–90% of human ...
Biyun Li, Laiyu Liu, Fei Li, Chunmei He, Yuan Chen, Xiaodong Tian, Zhenyu Liu, Weizhen Zhang   +7 more
doaj   +1 more source

Omadacycline for Diverse Infections in China: A Real-World Analysis of Efficacy and Safety

Infectious Diseases and Therapy
Introduction The efficacy and safety of omadacycline have been primarily documented through Phase III clinical trials; however, there are limited data from real-world clinical settings.
Weiwen Gao, Jian Yang, Xiangwang Zhang, Lei Tian, Dong Xu, Shuyun Xu, Dong Liu, Yan He   +7 more
doaj   +1 more source

Intravenous Versus Oral Omadacycline or Linezolid for Acute Bacterial Skin and Skin Infections: A post hoc Analysis of the OASIS Trials

Infectious Diseases and Therapy
Introduction Appropriate oral antibiotic therapy for the treatment of acute bacterial skin and skin structure infections (ABSSSI) is a challenge, as current oral treatment guidelines do not fully cover the most common skin pathogens.
George D. Rodriguez, Nathan Warren, Roman Yashayev, Surya Chitra, Maria Amodio-Groton, Kelly Wright   +5 more
doaj   +1 more source

Emergence of plasmid-borne tet(X4) resistance gene in clinical isolate of eravacycline- and omadacycline-resistant Klebsiella pneumoniae ST485

Microbiology Spectrum
Omadacycline and eravacycline are gradually being used as new tetracycline antibiotics for the clinical treatment of Gram-negative pathogens. Affected by various tetracycline-inactivating enzymes, there have been reports of resistance to eravacycline and
Xiaojing Liu, Yi Liu, Xiaohan Ma, Ruyan Chen, Chenyu Li, Hongxin Fu, Yu Yang, Kexin Guo, Xiaoping Zhang, Ruishan Liu, Hao Xu, Junfei Zhu, Beiwen Zheng   +12 more
doaj   +1 more source